NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered Retatrutide from Xingruida XDR? Mail in a sample (US only) and let us test it for free.

Test my supply
+4 more ↓
80%
Finnrick rating
#132 of 378 Retatrutide vendors
24 of 30 classifiable tests passed
customers 4.8★ (7)
methodology · Purity focus
Finnrick analysis · Retatrutide

Xingruida XDR Retatrutide shows a mostly recovered record, not a clean sheet: early purity misses and a recent -47% fill miss still weigh on it. Recent tests returned to passing, but batch identifiers are inconsistent.

methodology →
vendor intelligence report
Vendor Intelligence Report: Xingruida XDR

UK and Hong Kong filings resolve the storefront into a recent China-controlled export structure, with overdue compliance and unresolved HK directors. Infrastructure traces point to a sister peptide storefront sharing IP, nameservers and the same ASP/IIS template.

29 pages7 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutideselected
$0.99
80%
30
2
Tirzepatide
$0.33
79%
24
3
Ipamorelin
$0.90
74%
3
4
GHK-Cu
$0.08
71%
9
5
Melanotan II
$0.58
61%
2
6
PT-141
-
59%
3
7
Tesamorelin
$2.42
54%
10
8
BPC-157
$1.04
53%
8
9
TB-500
$1.74
42%
3
10
Cagrilintide
$3.38
-
0
12
Semaglutide
$2.14
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%20 Jun 2025: 57%24 Jul 2025: 61%4 Aug 2025: 63%21 Aug 2025: 63%1 Sep 2025: 61%4 Sep 2025: 64%4 Sep 2025: 65%10 Sep 2025: 67%18 Sep 2025: 69%30 Sep 2025: 72%5 Oct 2025: 74%29 Oct 2025: 75%4 Nov 2025: 76%14 Nov 2025: 78%17 Nov 2025: 78%17 Nov 2025: 75%23 Nov 2025: 76%25 Nov 2025: 77%25 Nov 2025: 78%25 Nov 2025: 79%15 Feb 2026: 81%26 Feb 2026: 81%13 Mar 2026: 82%8 May 2026: 79%25 May 2026: 80%5 Jun 2026: 81%30 Jul 2026: 81%9 Aug 2026: 82%12 Aug 2026: 83%12 Aug 2026: 80%29 Sep 2026: current 80%57%78%80%Jun 25Sep 26
Showing Retatrutide tests only
Free peptide testing

Ordered Retatrutide from Xingruida XDR? Mail in a sample (US only) and let us test it for free.

Test my supply
Xingruida XDR Retatrutide test history
COA-backed lab tests
1-10 of 30

About Xingruida XDR test results from Finnrick

Xingruida XDR is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 9 peptides and 92 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Xingruida XDR peptides in this dataset are BPC-157 (8 tests), GHK-Cu (9 tests) and Ipamorelin (3 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 92 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered Retatrutide from Xingruida XDR? Mail in a sample (US only) and let us test it for free.

Test my supply